Menu
Back to Journals » Infection and Drug Resistance » Volume 15
The Appropriateness to Use Fixed Assay Cut-Offs for Estimating Seroprevalence [Response to Letter]
Authors Alkharsah KR , Al-Afaleq AI
Received 10 January 2022
Accepted for publication 10 January 2022
Published 19 January 2022 Volume 2022:15 Pages 155—156
Khaled R Alkharsah,1 Adel I Al-Afaleq2
1Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Kingdom of Saudi Arabia; 2Department of Environmental Health, College of Public Health, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Kingdom of Saudi Arabia
Correspondence: Adel I Al-Afaleq, Email [email protected]
View the original paper by Dr Alkharsah and colleagues
This is in response to the Letter to the Editor
Dear editor
We were glad to read the letter to the editor by Da et al1 on our study.2 This indicates that our study attracted interest and added a value to the scientific community. We thank the colleagues for the constructive points they raised. We do have a common ground on some of the points however; other points were not so accurate. To enrich the scientific discussion, our reply to the raised points is as follows:
1. It is very well expected that the cut-off value affects the sensitivity and the specificity of an assay. Therefore, a fixed and defined rules for setting up the cut-off value should be followed throughout any assay to avoid interlaboratory variations and to make results comparable between different studies. The cut-off value in our assay is based on cut-off calibrators that are run with each experiment. Such procedure further minimizes the intraassay variability contrary to using fixed assay cut-off value that does not take into account the run-to-run variability. We disagree with our colleagues that “there are no definite rules of the choice of the cut-off value”. The cut-off value development, its quality control, and its calculation were very well described by the manufacturer. Hence, we felt that it is sufficient to refer the reader to the manufacturer’s instructions.
2. We agree with our colleagues on this point. We have stated the limitations of testing for WNV antibodies clearly and in many locations in the paper. We have also discussed these limitations in light of the assay procedures and epidemiological context.
3. As mentioned in the manuscript, our study is the first to estimate the seroprevalence of WNV antibodies in human and pigeons in the country. So, there is no population-based data available. However, the quantitative antibody detection approach is an interesting possibility and could be considered for future studies.
4. To confirm the transmission of WNV through blood donation, we have to confirm the presence of the WNV nucleic acid or its antigens in the donor blood samples, which was out of the scope of our study.
Disclosure
The authors declare no conflicts of interest in this communication.
References
1. Da Y, Wu Y, Quan P. The appropriateness to use fixed assay cut-offs for estimating seroprevalence.
2. Alkharsah KR, Al-Afaleq A. Serological evidence of West Nile virus infection among humans, horses, and pigeons in Saudi Arabia. Infect Drug Resist. 2021;14:5595–5601. doi:10.2147/IDR.S348648
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.